CAPRICOR THERAPEUTICS, INC. Accrued Liabilities, Current
CAPRICOR THERAPEUTICS, INC. (CAPR) had Accrued Liabilities, Current of $16.39 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2026-08-14
- 2026-06-30: Accrued Liabilities, Current $16.39M.
- 2026-03-31: Accrued Liabilities, Current $10.53M.
- 2025-12-31: Accrued Liabilities, Current $15.56M.
- 2025-09-30: Accrued Liabilities, Current $9.93M.
| Period end | Accrued Liabilities, Current |
|---|---|
| 2026-06-30 | $16.39M 10-Q · filed 2026-08-14 |
| 2026-03-31 | $10.53M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $15.56M 10-Q · filed 2026-08-14 |
| 2025-09-30 | $9.93M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $7.36M 10-Q · filed 2025-08-11 |
| 2025-03-31 | $4.24M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $4.91M 10-K · filed 2026-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |